|
|
|
|||||
Archive:
| |||||
intends to use the money to finish launching and expand the market for Dermagraft, which has been approved by the for treatment of diabetic foot ulcers. As part of the transaction, Safeguard's (NYSE:SFE) vice president for life sciences, Dr. Gary J. Kurtzman, has joined ABH's board of directors. (Philadelphia Business Journal, PA)
Scholl's Armstrong in Spain keynote: 'Amputations worse than cancer' Feb 23, 2007
Keynote at the Spanish National Symposium on the Diabetic Foot raises crucial questions and offers workshops on new technologies. The Spanish National Symposium on the Diabetic Foot last week was the scene for a keynote address that delivered a strong message proposing "a marriage of technology with common sense for the next decade." The address was delivered by David G. Armstrong, DPM, PhD, Professor of Surgery and Associate Dean at Scholl College at Rosalind Franklin University. (EurekAlert!)
Medical notes Feb 21, 2007
Care of the Diabetic Foot -- 7-8 p.m., Dunlap Memorial Hospital, 832 S. Main St., Orrville. Free. (Akron Beacon Journal, OH -- Living)
Hospitals to provide better patient care with recruitment of more nurses Feb 18, 2007
Sunday February 18, 2:17 PM. Hospitals are looking forward to recruiting more nurses, following the announcement of an additional 4,500 nurses to the workforce, to cater to healthcare needs. (Channel NewsAsia, Singapore)
Ugly Toenails May Be Fungal Infection in Diabetics Feb 14, 2007
Doctors "should be alert to our finding that, in patients at high risk for developing diabetic foot ulcerations, fungal infections of the toenails are common," Dr. Stephanie Wu, from Rosalind Franklin University of Medicine and Science in North Chicago, told Reuters Health. Wu also emphasized that just because a nail is thickened and discolored does not mean that there is a fungal infection. (MEDLINEplus)
Community News Feb 13, 2007
There will be a free health screening Tuesday at Gerrity s Supermarket in the Hanover Mall from 10 a.m. to 2 p.m. The event will include blood pressure and cholesterol screening, blood sugar check, breath and strength evaluations and diabetic foot care education. Also, take your medications with you and Mercy Special Care pharmacists will answer any questions you might have about dosage, side affects and more. (The Citizen's Voice, PA)
Basilea Reports 2006 Financial Results Jan 31, 2007
And in 2007, the announcement of second pivotal phase III study results for the treatment of complicated skin infections and infections in diabetic foot patients including Gram-negative pathogens showing high clinical cure rates, good safety and tolerability. Isavuconazole (BAL8557) - Broad-spectrum Antifungal Agent. (Primezone Releases)
Simple classification can help define and predict limb-threatening diabetic infections Jan 31, 2007
Research groups from Texas, Chicago, Washington State and the Netherlands partnered to publish a landmark study validating the Infectious Disease Society of America's guidelines for the clinical classification of diabetic foot infections. "We're all very pleased to see this study in print," noted co-author David G. Armstrong, DPM, PhD, Professor of Surgery at Scholl's Center for Lower Extremity Ambulatory Research (CLEAR) at Rosalind Franklin University. (EurekAlert!)
Phase 1/2 Clinical Trial Results to be Published Reporting Beneficial Effects of OrthoLogic's Chrysalin (TP508) in Treatment of Diabetic Foot Ulcers Jan 26, 2007
Jan. 25, 2007 (PRIME NEWSWIRE) -- OrthoLogic Corp. (NASDAQ: - ) today announced that an article by Fife, et al entitled ``Thrombin peptide Chrysalin(R) stimulates healing of diabetic foot ulcers in a placebo-controlled Phase I/II study'' will appear in the January 2007 edition of Wound Repair and Regeneration. The randomized, double-blind, placebo-controlled study describes statistically and clinically significant results achieved with twice-weekly topical application of Chrysalin, combined with... (Primezone Releases)
Basilea Announces Positive Top-Line Results On Second Pivotal Phase III Ceftobiprole Trial Jan 10, 2007
In particular, ceftobiprole, as a single agent, was clearly as effective as a combination regimen of standard broad-spectrum therapy in patients with difficult-to-treat diabetic foot infections,'' commented Dr. Rienk Pypstra, Chief Development Officer of Basilea ... Almost one third of patients had diabetic foot infections of which three quarters were moderate to severe cases ... The clinical response in patients with diabetic foot infections was 86% for ceftobiprole and 82% for comparator... (Primezone Releases)
Temperature Check May Prevent Diabetic Foot Ulcer Jan 10, 2007
NEW YORK (Reuters Health) - Adding a daily check of foot temperature with an infrared skin thermometer to standard diabetic foot therapy can significantly reduce the recurrence of foot ulcers, doctors in Texas and Chicago report in the medical journal Diabetes Care. The digital infrared thermometer, called TempTouch, costs approximately $150 and is powered by 9-V batteries, Don Lawson, CEO of the thermometer maker Xilas Medical, told Reuters Health. (MEDLINEplus)
Focusing on treatment Western medicine passed by Jan 10, 2007
The patients come from the U.S., Canada, Britain, Israel, Turkey or South Africa, all nursing some kind of bacterial infection that won't heal: a diabetic foot ulcer, chronic sinusitis, an open festering wound, a 15-year urinary tract infection that's proven resistant to every antibiotic thrown its way. They come for phage therapy. (San Jose Business Journal, CA)
Hospital to hold health fair Jan 4, 2007
Quality Medical Equipment will conduct diabetic foot scans during the fair, and Connie Arrington, an osteoporosis coordinator with the state Department of Health, will provide bone density heel scan testing for osteoporosis. The hospital's Wellness Center staff will measure height/weight body mass indexes. (Greenwood Commonwealth, MS)
Back to FindHealthNews Home
©1998-2006 SurfWax, Inc.
All rights reserved. Patents pending.
Copyright SurfWax, Inc. 2006 |